Prior To US Price Negotiations, AbbVie Charges $2.1 Billion For A Cancer Medication
Ahead of government price talks for its best-selling cancer treatment Imbruvica, AbbVie announced on Friday a $2.1 billion charge associated with anticipated revenue declines following the implementation of the new price for Medicare patients in the United States. With a declared government objective of saving $25 billion annually on drug costs by 2031, the Illinois-based…









